Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 308

1.

Author Correction: Targeting cardiac fibrosis with engineered T cells.

Aghajanian H, Kimura T, Rurik JG, Hancock AS, Leibowitz MS, Li L, Scholler J, Monslow J, Lo A, Han W, Wang T, Bedi K, Morley MP, Saldana RAL, Bolar NA, McDaid K, Assenmacher CA, Smith CL, Wirth D, June CH, Margulies KB, Jain R, Puré E, Albelda SM, Epstein JA.

Nature. 2019 Nov 14. doi: 10.1038/s41586-019-1761-7. [Epub ahead of print]

PMID:
31723271
2.

Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy.

Thompson JC, Hwang WT, Davis C, Deshpande C, Jeffries S, Rajpurohit Y, Krishna V, Smirnov D, Verona R, Lorenzi MV, Langer CJ, Albelda SM.

Lung Cancer. 2019 Oct 18;139:1-8. doi: 10.1016/j.lungcan.2019.10.012. [Epub ahead of print]

3.

Targeting cardiac fibrosis with engineered T cells.

Aghajanian H, Kimura T, Rurik JG, Hancock AS, Leibowitz MS, Li L, Scholler J, Monslow J, Lo A, Han W, Wang T, Bedi K, Morley MP, Linares Saldana RA, Bolar NA, McDaid K, Assenmacher CA, Smith CL, Wirth D, June CH, Margulies KB, Jain R, Puré E, Albelda SM, Epstein JA.

Nature. 2019 Sep;573(7774):430-433. doi: 10.1038/s41586-019-1546-z. Epub 2019 Sep 11. Erratum in: Nature. 2019 Nov 14;:.

PMID:
31511695
4.

Phenotypic and functional analysis of malignant mesothelioma tumor-infiltrating lymphocytes.

Klampatsa A, O'Brien SM, Thompson JC, Rao AS, Stadanlick JE, Martinez MC, Liousia M, Cantu E, Cengel K, Moon EK, Singhal S, Eruslanov EB, Albelda SM.

Oncoimmunology. 2019 Jul 13;8(9):e1638211. doi: 10.1080/2162402X.2019.1638211. eCollection 2019.

PMID:
31428531
5.

Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers.

Haas AR, Tanyi JL, O'Hara MH, Gladney WL, Lacey SF, Torigian DA, Soulen MC, Tian L, McGarvey M, Nelson AM, Farabaugh CS, Moon E, Levine BL, Melenhorst JJ, Plesa G, June CH, Albelda SM, Beatty GL.

Mol Ther. 2019 Nov 6;27(11):1919-1929. doi: 10.1016/j.ymthe.2019.07.015. Epub 2019 Jul 30.

PMID:
31420241
6.

Loss of cells expressing fibroblast activation protein has variable effects in models of TGF-β and chronic bleomycin-induced fibrosis.

Kimura T, Monslow J, Klampatsa A, Leibowitz M, Sun J, Liousia M, Woodruff P, Moon E, Todd L, Puré E, Albelda SM.

Am J Physiol Lung Cell Mol Physiol. 2019 Aug 1;317(2):L271-L282. doi: 10.1152/ajplung.00071.2019. Epub 2019 Jun 12.

PMID:
31188013
7.

Function of Human Tumor-Infiltrating Lymphocytes in Early-Stage Non-Small Cell Lung Cancer.

O'Brien SM, Klampatsa A, Thompson JC, Martinez MC, Hwang WT, Rao AS, Standalick JE, Kim S, Cantu E, Litzky LA, Singhal S, Eruslanov EB, Moon EK, Albelda SM.

Cancer Immunol Res. 2019 Jun;7(6):896-909. doi: 10.1158/2326-6066.CIR-18-0713. Epub 2019 May 3.

PMID:
31053597
8.

Synthetic secoisolariciresinol diglucoside (LGM2605) inhibits Libby amphibole fiber-induced acute inflammation in mice.

Christofidou-Solomidou M, Pietrofesa RA, Park K, Albelda SM, Serve KM, Keil DE, Pfau JC.

Toxicol Appl Pharmacol. 2019 Jul 15;375:81-93. doi: 10.1016/j.taap.2019.04.018. Epub 2019 Apr 23.

PMID:
31022494
9.

Human tumor-associated monocytes/macrophages and their regulation of T cell responses in early-stage lung cancer.

Singhal S, Stadanlick J, Annunziata MJ, Rao AS, Bhojnagarwala PS, O'Brien S, Moon EK, Cantu E, Danet-Desnoyers G, Ra HJ, Litzky L, Akimova T, Beier UH, Hancock WW, Albelda SM, Eruslanov EB.

Sci Transl Med. 2019 Feb 13;11(479). pii: eaat1500. doi: 10.1126/scitranslmed.aat1500.

10.

Molecular Characterization of Malignant Mesothelioma: Time for New Targets?

Aggarwal C, Albelda SM.

Cancer Discov. 2018 Dec;8(12):1508-1510. doi: 10.1158/2159-8290.CD-18-1181.

PMID:
30510013
11.

Luminol Chemiluminescence Reports Photodynamic Therapy-Generated Neutrophil Activity In Vivo and Serves as a Biomarker of Therapeutic Efficacy.

Davis RW 4th, Snyder E, Miller J, Carter S, Houser C, Klampatsa A, Albelda SM, Cengel KA, Busch TM.

Photochem Photobiol. 2019 Jan;95(1):430-438. doi: 10.1111/php.13040. Epub 2018 Nov 26.

PMID:
30357853
12.

A preclinical model to investigate the role of surgically-induced inflammation in tumor responses to intraoperative photodynamic therapy.

Davis RW 4th, Papasavvas E, Klampatsa A, Putt M, Montaner LJ, Culligan MJ, McNulty S, Friedberg JS, Simone CB 2nd, Singhal S, Albelda SM, Cengel KA, Busch TM.

Lasers Surg Med. 2018 Jul;50(5):440-450. doi: 10.1002/lsm.22934. Epub 2018 May 25.

13.

Epigenomic-Guided Mass Cytometry Profiling Reveals Disease-Specific Features of Exhausted CD8 T Cells.

Bengsch B, Ohtani T, Khan O, Setty M, Manne S, O'Brien S, Gherardini PF, Herati RS, Huang AC, Chang KM, Newell EW, Bovenschen N, Pe'er D, Albelda SM, Wherry EJ.

Immunity. 2018 May 15;48(5):1029-1045.e5. doi: 10.1016/j.immuni.2018.04.026.

14.

Phase I Study of Intrapleural Gene-Mediated Cytotoxic Immunotherapy in Patients with Malignant Pleural Effusion.

Aggarwal C, Haas AR, Metzger S, Aguilar LK, Aguilar-Cordova E, Manzanera AG, Gómez-Hernández G, Katz SI, Alley EW, Evans TL, Bauml JM, Cohen RB, Langer CJ, Albelda SM, Sterman DH.

Mol Ther. 2018 May 2;26(5):1198-1205. doi: 10.1016/j.ymthe.2018.02.015. Epub 2018 Feb 21.

15.

Novel therapies for malignant pleural mesothelioma.

Scherpereel A, Wallyn F, Albelda SM, Munck C.

Lancet Oncol. 2018 Mar;19(3):e161-e172. doi: 10.1016/S1470-2045(18)30100-1. Review.

PMID:
29508763
16.

Synthetic Lignan Secoisolariciresinol Diglucoside (LGM2605) Reduces Asbestos-Induced Cytotoxicity in an Nrf2-Dependent and -Independent Manner.

Pietrofesa RA, Chatterjee S, Park K, Arguiri E, Albelda SM, Christofidou-Solomidou M.

Antioxidants (Basel). 2018 Mar 2;7(3). pii: E38. doi: 10.3390/antiox7030038.

17.

Human neutrophils can mimic myeloid-derived suppressor cells (PMN-MDSC) and suppress microbead or lectin-induced T cell proliferation through artefactual mechanisms.

Negorev D, Beier UH, Zhang T, Quatromoni JG, Bhojnagarwala P, Albelda SM, Singhal S, Eruslanov E, Lohoff FW, Levine MH, Diamond JM, Christie JD, Hancock WW, Akimova T.

Sci Rep. 2018 Feb 16;8(1):3135. doi: 10.1038/s41598-018-21450-6.

18.

Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines.

Moon EK, Wang LS, Bekdache K, Lynn RC, Lo A, Thorne SH, Albelda SM.

Oncoimmunology. 2018 Jan 9;7(3):e1395997. doi: 10.1080/2162402X.2017.1395997. eCollection 2018.

19.

The Synthetic Lignan Secoisolariciresinol Diglucoside Prevents Asbestos-Induced NLRP3 Inflammasome Activation in Murine Macrophages.

Pietrofesa RA, Woodruff P, Hwang WT, Patel P, Chatterjee S, Albelda SM, Christofidou-Solomidou M.

Oxid Med Cell Longev. 2017;2017:7395238. doi: 10.1155/2017/7395238. Epub 2017 Sep 13.

20.

Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM).

Klampatsa A, Haas AR, Moon EK, Albelda SM.

Cancers (Basel). 2017 Sep 1;9(9). pii: E115. doi: 10.3390/cancers9090115. Review.

21.

Human lung tumor FOXP3+ Tregs upregulate four "Treg-locking" transcription factors.

Akimova T, Zhang T, Negorev D, Singhal S, Stadanlick J, Rao A, Annunziata M, Levine MH, Beier UH, Diamond JM, Christie JD, Albelda SM, Eruslanov EB, Hancock WW.

JCI Insight. 2017 Aug 17;2(16). pii: 94075. doi: 10.1172/jci.insight.94075. eCollection 2017 Aug 17.

22.

Mouse versus Human Neutrophils in Cancer: A Major Knowledge Gap.

Eruslanov EB, Singhal S, Albelda SM.

Trends Cancer. 2017 Feb;3(2):149-160. doi: 10.1016/j.trecan.2016.12.006. Epub 2017 Jan 19. Review.

23.

The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System.

Moon EK, Langer CJ, Albelda SM.

Ann Am Thorac Soc. 2017 Aug;14(8):1248-1260. doi: 10.1513/AnnalsATS.201702-152FR. Review.

PMID:
28613923
24.

Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients.

Condamine T, Dominguez GA, Youn JI, Kossenkov AV, Mony S, Alicea-Torres K, Tcyganov E, Hashimoto A, Nefedova Y, Lin C, Partlova S, Garfall A, Vogl DT, Xu X, Knight SC, Malietzis G, Lee GH, Eruslanov E, Albelda SM, Wang X, Mehta JL, Bewtra M, Rustgi A, Hockstein N, Witt R, Masters G, Nam B, Smirnov D, Sepulveda MA, Gabrilovich DI.

Sci Immunol. 2016 Aug;1(2). pii: aaf8943. doi: 10.1126/sciimmunol.aaf8943. Epub 2016 Aug 5.

25.

Tumor-associated neutrophils display a distinct N1 profile following TGFβ modulation: A transcriptomics analysis of pro- vs. antitumor TANs.

Shaul ME, Levy L, Sun J, Mishalian I, Singhal S, Kapoor V, Horng W, Fridlender G, Albelda SM, Fridlender ZG.

Oncoimmunology. 2016 Sep 13;5(11):e1232221. doi: 10.1080/2162402X.2016.1232221. eCollection 2016.

26.

CAR T Cell Therapy for Solid Tumors.

Newick K, O'Brien S, Moon E, Albelda SM.

Annu Rev Med. 2017 Jan 14;68:139-152. doi: 10.1146/annurev-med-062315-120245. Epub 2016 Nov 17. Review.

PMID:
27860544
27.

Diacylglycerol Kinases (DGKs): Novel Targets for Improving T Cell Activity in Cancer.

Riese MJ, Moon EK, Johnson BD, Albelda SM.

Front Cell Dev Biol. 2016 Oct 17;4:108. eCollection 2016. Review.

28.

Ubiquitin-specific Protease-7 Inhibition Impairs Tip60-dependent Foxp3+ T-regulatory Cell Function and Promotes Antitumor Immunity.

Wang L, Kumar S, Dahiya S, Wang F, Wu J, Newick K, Han R, Samanta A, Beier UH, Akimova T, Bhatti TR, Nicholson B, Kodrasov MP, Agarwal S, Sterner DE, Gu W, Weinstock J, Butt TR, Albelda SM, Hancock WW.

EBioMedicine. 2016 Nov;13:99-112. doi: 10.1016/j.ebiom.2016.10.018. Epub 2016 Oct 15.

29.

Valproic acid improves second-line regimen of small cell lung carcinoma in preclinical models.

Hubaux R, Vandermeers F, Cosse JP, Crisanti C, Kapoor V, Albelda SM, Mascaux C, Delvenne P, Hubert P, Willems L.

ERJ Open Res. 2015 Oct 19;1(2). pii: 00028-2015. eCollection 2015 Oct.

30.

Early detection of pemetrexed-induced inhibition of thymidylate synthase in non-small cell lung cancer with FLT-PET imaging.

Chen X, Yang Y, Berger I, Khalid U, Patel A, Cai J, Farwell MD, Langer C, Aggarwal C, Albelda SM, Katz SI.

Oncotarget. 2017 Apr 11;8(15):24213-24223. doi: 10.18632/oncotarget.12085.

31.

Origin and Role of a Subset of Tumor-Associated Neutrophils with Antigen-Presenting Cell Features in Early-Stage Human Lung Cancer.

Singhal S, Bhojnagarwala PS, O'Brien S, Moon EK, Garfall AL, Rao AS, Quatromoni JG, Stephen TL, Litzky L, Deshpande C, Feldman MD, Hancock WW, Conejo-Garcia JR, Albelda SM, Eruslanov EB.

Cancer Cell. 2016 Jul 11;30(1):120-135. doi: 10.1016/j.ccell.2016.06.001. Epub 2016 Jun 30.

32.

Chimeric antigen receptor T-cell therapy for solid tumors.

Newick K, Moon E, Albelda SM.

Mol Ther Oncolytics. 2016 Apr 13;3:16006. doi: 10.1038/mto.2016.6. eCollection 2016. Review.

33.

Augmentation of CAR T-cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase A Localization.

Newick K, O'Brien S, Sun J, Kapoor V, Maceyko S, Lo A, Puré E, Moon E, Albelda SM.

Cancer Immunol Res. 2016 Jun;4(6):541-51. doi: 10.1158/2326-6066.CIR-15-0263. Epub 2016 Apr 4.

34.

Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy.

Sterman DH, Alley E, Stevenson JP, Friedberg J, Metzger S, Recio A, Moon EK, Haas AR, Vachani A, Katz SI, Sun J, Heitjan DF, Hwang WT, Litzky L, Yearley JH, Tan KS, Papasavvas E, Kennedy P, Montaner LJ, Cengel KA, Simone CB 2nd, Culligan M, Langer CJ, Albelda SM.

Clin Cancer Res. 2016 Aug 1;22(15):3791-800. doi: 10.1158/1078-0432.CCR-15-2133. Epub 2016 Mar 11.

35.

CD11b+Ly6G+ cells inhibit tumor growth by suppressing IL-17 production at early stages of tumorigenesis.

Liu Y, O'Leary CE, Wang LS, Bhatti TR, Dai N, Kapoor V, Liu P, Mei J, Guo L, Oliver PM, Albelda SM, Worthen GS.

Oncoimmunology. 2015 Jul 28;5(1):e1061175. eCollection 2016.

36.

Asbestos Induces Oxidative Stress and Activation of Nrf2 Signaling in Murine Macrophages: Chemopreventive Role of the Synthetic Lignan Secoisolariciresinol Diglucoside (LGM2605).

Pietrofesa RA, Velalopoulou A, Albelda SM, Christofidou-Solomidou M.

Int J Mol Sci. 2016 Mar 1;17(3):322. doi: 10.3390/ijms17030322.

37.

Flaxseed lignans enriched in secoisolariciresinol diglucoside prevent acute asbestos-induced peritoneal inflammation in mice.

Pietrofesa RA, Velalopoulou A, Arguiri E, Menges CW, Testa JR, Hwang WT, Albelda SM, Christofidou-Solomidou M.

Carcinogenesis. 2016 Feb;37(2):177-87. doi: 10.1093/carcin/bgv174. Epub 2015 Dec 17.

38.

The Optical Biopsy: A Novel Technique for Rapid Intraoperative Diagnosis of Primary Pulmonary Adenocarcinomas.

Kennedy GT, Okusanya OT, Keating JJ, Heitjan DF, Deshpande C, Litzky LA, Albelda SM, Drebin JA, Nie S, Low PS, Singhal S.

Ann Surg. 2015 Oct;262(4):602-9. doi: 10.1097/SLA.0000000000001452.

PMID:
26366539
39.

Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer.

Moon EK, Ranganathan R, Eruslanov E, Kim S, Newick K, O'Brien S, Lo A, Liu X, Zhao Y, Albelda SM.

Clin Cancer Res. 2016 Jan 15;22(2):436-47. doi: 10.1158/1078-0432.CCR-15-1070. Epub 2015 Aug 31.

40.

Promoting metastasis: neutrophils and T cells join forces.

Fridlender ZG, Albelda SM, Granot Z.

Cell Res. 2015 Jul;25(7):765-6. doi: 10.1038/cr.2015.62. Epub 2015 May 26.

41.

Bioanalytical techniques for detecting biomarkers of response to human asbestos exposure.

Mesaros C, Worth AJ, Snyder NW, Christofidou-Solomidou M, Vachani A, Albelda SM, Blair IA.

Bioanalysis. 2015;7(9):1157-73. doi: 10.4155/bio.15.53. Review.

42.

Surgical cytoreduction restores the antitumor efficacy of a Listeria monocytogenes vaccine in malignant pleural mesothelioma.

Kennedy GT, Judy BF, Bhojnagarwala P, Moon EK, Fridlender ZG, Albelda SM, Singhal S.

Immunol Lett. 2015 Jul;166(1):28-35. doi: 10.1016/j.imlet.2015.05.009. Epub 2015 May 18.

43.

Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells.

Lo A, Wang LS, Scholler J, Monslow J, Avery D, Newick K, O'Brien S, Evans RA, Bajor DJ, Clendenin C, Durham AC, Buza EL, Vonderheide RH, June CH, Albelda SM, Puré E.

Cancer Res. 2015 Jul 15;75(14):2800-2810. doi: 10.1158/0008-5472.CAN-14-3041. Epub 2015 May 15.

44.

Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer.

Eruslanov EB, Bhojnagarwala PS, Quatromoni JG, Stephen TL, Ranganathan A, Deshpande C, Akimova T, Vachani A, Litzky L, Hancock WW, Conejo-Garcia JR, Feldman M, Albelda SM, Singhal S.

J Clin Invest. 2014 Dec;124(12):5466-80. doi: 10.1172/JCI77053. Epub 2014 Nov 10.

45.

An optimized disaggregation method for human lung tumors that preserves the phenotype and function of the immune cells.

Quatromoni JG, Singhal S, Bhojnagarwala P, Hancock WW, Albelda SM, Eruslanov E.

J Leukoc Biol. 2015 Jan;97(1):201-9. doi: 10.1189/jlb.5TA0814-373. Epub 2014 Oct 30.

46.

Intraoperative near-infrared imaging can identify pulmonary nodules.

Okusanya OT, Holt D, Heitjan D, Deshpande C, Venegas O, Jiang J, Judy R, DeJesus E, Madajewski B, Oh K, Wang M, Albelda SM, Nie S, Singhal S.

Ann Thorac Surg. 2014 Oct;98(4):1223-30. doi: 10.1016/j.athoracsur.2014.05.026. Epub 2014 Aug 5.

47.

Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors.

Moon EK, Wang LC, Dolfi DV, Wilson CB, Ranganathan R, Sun J, Kapoor V, Scholler J, Puré E, Milone MC, June CH, Riley JL, Wherry EJ, Albelda SM.

Clin Cancer Res. 2014 Aug 15;20(16):4262-73. doi: 10.1158/1078-0432.CCR-13-2627. Epub 2014 Jun 11.

48.

Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity.

Wang LC, Lo A, Scholler J, Sun J, Majumdar RS, Kapoor V, Antzis M, Cotner CE, Johnson LA, Durham AC, Solomides CC, June CH, Puré E, Albelda SM.

Cancer Immunol Res. 2014 Feb;2(2):154-66. doi: 10.1158/2326-6066.CIR-13-0027. Epub 2013 Nov 12.

49.

T cells expressing chimeric antigen receptors can cause anaphylaxis in humans.

Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X, Zhao Y, Kalos M, June CH.

Cancer Immunol Res. 2013 Jul;1(1):26-31. doi: 10.1158/2326-6066.CIR-13-0006. Epub 2013 Apr 7.

50.

Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.

Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, Chew A, Zhao Y, Levine BL, Albelda SM, Kalos M, June CH.

Cancer Immunol Res. 2014 Feb;2(2):112-20. doi: 10.1158/2326-6066.CIR-13-0170. Erratum in: Cancer Immunol Res. 2015 Feb;3(2):217.

Supplemental Content

Loading ...
Support Center